Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge

Fischer, Laurent; Tronel, J.P.; Pardo-David, Camilla; Tanner, Patrick A.; Colombet, G; Minke, J.M.; Audonnet, Jean-Christophe

doi:10.1016/s0264-410x(02)00344-4

Cited by 51 publications

(36 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The insertion of a glycoprotein cDNA expression cassette into the deleted E3 region, and obtaining the recombinant CAV-2 genome bearing the foreign gene were all performed in vitro by means of DNA manipulation; and, secondly, the recombinant virus was recovered by simply transfecting the recombinant genome into MDCK cells. There was no contamination with wild virus that did not contain the foreign gene; thus there was no need for a round of plaque screening and purification of the recombinant virus [15]. Once the CPE appeared, it indicated that the recombinant virus was generated.…”

Section: Discussionmentioning

confidence: 99%

“…Avirulent canine adenovirus type-2 (CAV-2) is a safe vaccine used for canine infectious hepatitis and canine infectious laryngotracheitis. A recombinant vaccine bearing canine distemper virus antigen has been constructed by homologous recombination and this recombinant vaccine was proved to stimulate a protective response in dogs and minks [15]. It was suggested that CAV-2 is suitable for expressing protective antigens of viruses that infect dogs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein

Zhang

Fooks³

et al. 2006

Microbes and Infection

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein

Zhang

Fooks³

et al. 2006

Microbes and Infection

View full text Add to dashboard Cite

“…Most of the past efforts focused on human Ads, such as those of the common serotype 5 (AdHu5), which cause mild upper respiratory symptoms upon natural infections. Both replication competent 9,10 and E1-deleted (DE1) replication-defective AdHu5 vectors have been developed as vaccine carriers and have shown efficacy in mice, 11 dogs 12,13 and nonhuman primates (NHPs). 7 E1-deleted AdHu5 vectors also performed well in clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Chimpanzee-origin adenovirus vectors as vaccine carriers

et al. 2005

View full text Add to dashboard Cite

Vaccines based on replication-defective adenoviral vectors are being developed for infectious agents and tumorassociated antigens. Early work focused on vaccines derived from a common human serotype of adenovirus, that is, adenovirus of the serotype 5 (AdHu5). Neutralizing antibodies against AdHu5 virus, present in a large percentage of the human population, dampen the efficacy of vaccines based on this carrier. To circumvent this problem, we generated vectors derived from chimpanzee adenoviruses.Here we describe some basic parameters of vectors derived from chimpanzee adenoviruses C68 and C7, including growth characteristics, yields of infectious particles, effects of additional deletions in E3 and E4 and lengths of the inserted foreign sequence as they relate to the suitability for their eventual development as vaccine carriers for clinical use.

show abstract

“…For CDV, the residual virulence of live-attenuated vaccines for highly susceptible species led to continued interest in this approach. The potential of various recombinant vaccine platforms expressing CDV glycoproteins has been explored (39,40), and a CDV H protein-and F protein-expressing canarypox virus vector is licensed in several countries for use in dogs and ferrets (11). While all of these approaches involve at least a single round of infection in the vaccinee, the RABV vaccine platform is inactivated and as such is no longer considered a genetically modified organism (GMO).…”

Section: Efficacy Of Bivalent Rabv-cdv Vaccines Journal Of Virologymentioning

confidence: 99%

Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens

Budaszewski

Hudacek

Sawatsky

et al. 2017

J Virol

View full text Add to dashboard Cite

The development of multivalent vaccines is an attractive methodology for the simultaneous prevention of several infectious diseases in vulnerable populations. Both canine distemper virus (CDV) and rabies virus (RABV) cause lethal disease in wild and domestic carnivores. While RABV vaccines are inactivated, the liveattenuated CDV vaccines retain residual virulence for highly susceptible wildlife species. In this study, we developed recombinant bivalent vaccine candidates based on recombinant vaccine strain rabies virus particles, which concurrently display the protective CDV and RABV glycoprotein antigens. The recombinant viruses replicated to near-wild-type titers, and the heterologous glycoproteins were efficiently expressed and incorporated in the viral particles. Immunization of ferrets with beta-propiolactone-inactivated recombinant virus particles elicited protective RABV antibody titers, and animals immunized with a combination of CDV attachment protein-and fusion protein-expressing recombinant viruses were protected from lethal CDV challenge. However, animals that were immunized with only a RABV expressing the attachment protein of CDV vaccine strain Onderstepoort succumbed to infection with a more recent wild-type strain, indicating that immune responses to the more conserved fusion protein contribute to protection against heterologous CDV strains.IMPORTANCE Rabies virus and canine distemper virus (CDV) cause high mortality rates and death in many carnivores. While rabies vaccines are inactivated and thus have an excellent safety profile and high stability, live-attenuated CDV vaccines can retain residual virulence in highly susceptible species. Here we generated recombinant inactivated rabies viruses that carry one of the CDV glycoproteins on their surface. Ferrets immunized twice with a mix of recombinant rabies viruses carrying the CDV fusion and attachment glycoproteins were protected from lethal CDV challenge, whereas all animals that received recombinant rabies viruses carrying only the CDV attachment protein according to the same immunization scheme died. Irrespective of the CDV antigens used, all animals developed protective titers against rabies virus, illustrating that a bivalent rabies virus-based vaccine against CDV induces protective immune responses against both pathogens.

show abstract

Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge

Cited by 51 publications

References 28 publications

Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein

Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein

Chimpanzee-origin adenovirus vectors as vaccine carriers

Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens

Contact Info

Product

Resources

About